Table 1 Chronicle of the genetic tests and risk-reducing salpingo-oophorectomy (RRSO) for the reported family
Date | Events |
|---|---|
January, 2018 | The proband (III-7) received a 25-gene panel targeted genetic test and was confirmed as deleterious BRCA1 carrier. |
February to March, 2018 | Pedigree validation was performed for nine family members (II-5, III-5, 9, 11, 12, IV-2, 3, 4, 5), and seven (II-5, III-5, 9, 11, 12, IV-4, 5) were confirmed as deleterious mutation carriers. |
April, 2018 | One family member (III-11) was diagnosed with high-grade serous ovarian carcinoma of stage IV. She accepted neoadjuvant chemotherapy and interval debulking surgery. |
May, 2018 | One family member (III-9) accepted RRSO and hysterectomy, and was diagnosed with primary carcinoma of the fallopian tube of Stage IA (lesion size of 0.5 mm). She asked for observation and refused further therapy. |